Ind-Swift Laboratories Ltd. (INDSWFTLAB) AI Stock Analysis

• Market Cap: ₹6.16B
• Dividend Yield: N/A
• Average Volume (3M): 5.55K
• Price to Earnings (P/E): 3.0
• Beta (1Y): 1.24
• Revenue Growth: -68.96%
• EPS Growth: -30.30%
• Country: IN
• Employees: 47
• Sector: Healthcare
• Sector Strength: 51
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 60,618,860
• 10 Day Avg. Volume: 4,057
• 30 Day Avg. Volume: 5,553
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹106.00
• Price Target Upside: 4.29% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 62 Neutral
• Price Target: ₹106.00 ▲(4.29% Upside)

Ind-Swift Laboratories Ltd. has a solid financial foundation with strong revenue growth and profitability, but faces significant cash flow challenges that could impact liquidity. The stock's undervaluation presents potential upside, though technical indicators suggest caution. The absence of earnings call and corporate events data limits further insights.

Ind-Swift Laboratories Ltd. Business Overview & Revenue Model

Company Description

Ind-Swift Laboratories Ltd. is a pharmaceutical company based in India, specializing in the manufacturing and marketing of a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs), finished dosage forms, and formulations. The company operates in various therapeutic segments, such as cardiology, neurology, and gastroenterology, and is committed to providing high-quality medicines and healthcare solutions.

How the Company Makes Money

Ind-Swift Laboratories Ltd. generates revenue primarily through the sale of its pharmaceutical products, which include APIs and finished formulations. The company's revenue model is built on both domestic and international sales, with a significant portion of its earnings coming from exports to various countries. Key revenue streams include bulk drug sales to other pharmaceutical companies, direct sales of branded and generic medications, and contract manufacturing services. Additionally, strategic partnerships with other pharmaceutical firms, licensing agreements, and collaborations for research and development activities contribute to the company's earnings by expanding its market reach and enhancing its product portfolio.

Ind-Swift Laboratories Ltd. Financial Statement Overview

Summary

Ind-Swift Laboratories Ltd. shows strong revenue growth and profitability with a robust balance sheet and low leverage. However, significant cash flow challenges indicate potential liquidity issues, necessitating improved cash management strategies.

Income Statement

Ind-Swift Laboratories Ltd. has shown a strong revenue growth rate of 25.63% in the latest year, indicating robust sales expansion. However, the company experienced a significant drop in EBIT, resulting in a negative EBIT margin for 2025. Despite this, the net profit margin remains healthy due to a substantial net income, suggesting effective cost management or one-time gains.

Balance Sheet

The balance sheet reflects a strong equity position with a low debt-to-equity ratio of 0.0178 in 2025, indicating financial stability and low leverage. The return on equity is impressive at 44.97%, showcasing efficient use of equity to generate profits. The equity ratio is solid, suggesting a stable financial structure.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows in 2025, indicating potential liquidity issues. The free cash flow growth rate is negative, suggesting declining cash generation capabilities. The ratios of operating and free cash flow to net income are unfavorable, highlighting cash flow management concerns.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2021	Dec 2021
Income Statement
Total Revenue	4.47B	5.62B	12.81B	12.07B	8.91B	10.39B
Gross Profit	338.82M	2.74B	4.13B	4.40B	3.75B	4.10B
EBITDA	3.88B	2.85B	6.86B	2.36B	1.98B	2.39B
Net Income	2.40B	2.50B	4.21B	475.97M	-31.47M	-21.49M
Balance Sheet
Total Assets	0.00	14.38B	11.65B	18.24B	18.18B	18.01B
Cash, Cash Equivalents and Short-Term Investments	4.38B	4.82B	4.32B	231.54M	199.03M	333.68M
Total Debt	0.00	408.41M	166.22M	8.62B	10.05B	9.53B
Total Liabilities	-10.12B	2.65B	2.34B	11.42B	12.15B	12.00B
Stockholders Equity	10.12B	11.73B	9.36B	6.82B	6.04B	6.01B
Cash Flow
Free Cash Flow	0.00	-898.80M	-2.08B	1.82B	1.31B	1.32B
Operating Cash Flow	0.00	-254.74M	-1.63B	1.95B	1.35B	1.50B
Investing Cash Flow	0.00	-1.10B	-1.23B	-133.68M	-101.72M	47.72M
Financing Cash Flow	0.00	692.05M	6.99B	-1.86B	-1.24B	-1.41B

Ind-Swift Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 101.64
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDSWFTLAB, the sentiment is Positive. The current price of 101.64 is above the 20-day moving average (MA) of 100.10, below the 50-day MA of 104.86, and above the 200-day MA of 97.80, indicating a neutral trend. The MACD of -0.94 indicates Negative momentum. The RSI at 52.36 is Neutral, neither overbought nor oversold. The STOCH value of 81.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:INDSWFTLAB.

Ind-Swift Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹6.19B	11.51		―	9.15%	88.32%
INDSWFTLAB	62 Neutral	₹6.16B	2.97		―	-68.96%	-30.30%
SAKAR	61 Neutral	₹7.48B	37.86		―	21.65%	73.84%
MEDICAMEQ	54 Neutral	₹4.71B	47.59		0.29%	-9.90%	33.18%
ZIMLAB	54 Neutral	₹3.65B	38.92		―	-3.36%	-47.58%
Sector *	51 Neutral	$7.92B	-0.43	-41.69%	2.21%	22.29%	-1.85%
NECLIFE	43 Neutral	₹3.29B	30.02		―	-3.41%	-3028.44%